Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research, Nuclear Structure and Function, and RNA Research and Splicing.
Remibrutinib (Rhapsido) for chronic spontaneous urticaria
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in <i>TP53</i> -mutated myeloid malignancies
Therapeutic potential of STK17A targeted therapies
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.
Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML
Big cells, bigger BTK resistance in mantle cell lymphoma.
Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy.
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings.
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance.
Supplementary Figure S1 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figure S3 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Table S2 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figures S1-S8 from Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
Supplementary Table S3 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Methods from Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
Supplementary Figure S6 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Tables from Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
Data from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United States
Supplementary Figure S4 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figure S5 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figure S2 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Table S1 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figure S7 from <i>XPO1</i><sup><i>R749Q</i></sup> Mutations Co-occur with <i>POLE</i> Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
BTK inhibitors: past, present, and future